Biogen Idec to present study data on Tysabri

Biogen Idec is to present data from clinical studies on its multiple sclerosis (MS) treatment Tysabri, demonstrating its numerous potential benefits.

The pharmaceutical company will be giving 15 separate presentations at the American Academy of Neurology’s (AAN) 62nd Annual Meeting this week to highlight results from a number of separate trials.

These studies have revealed that the drug can bring a number of improvements among certain patients, including better cognition and sustained visual function, lower levels of fatigue and disability and an overall higher quality of life.

Dr Alfred Sandrock, senior vice-president of neurology research and development at Biogen Idec, said this data will add to the “growing body of scientific evidence” supporting the treatment’s effectiveness.

He added: “Tysabri continues to change the way neurologists and patients define success in the treatment of MS.”

Other MS drugs the company will be showcasing at the AAN event include the prolonged-release treatment fampridine, which is designed to improve walking ability.